The role of PARP inhibitors in BC adjuvant therapy has been investigated by the OlympiA trial [73], a phase 3 randomized study that evaluated the role of poly(adenosine diphosphate-ribose) polymerase inhibitor Olaparib in HER2 negative early BC with BRCA1/BRCA2 germline pathogenic or likely pathogenic variant at high risk of recurrence. The gene discussed is BRCA2; the disease is breast cancer.